Alex P. Hamilton
Known title: DirectorCIK: 0001970448
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
ATXG Joins 12 Industrial Stocks Moving in Pre‑Market. ATXG was among 12 industrial stocks that saw movement in the pre‑market session on Wednesday. The move comes as the stock trades near its 10‑touch support level of $3.63 and a moderate RSI of 43.2. This activity may signal early interest from traders ahead of the market open. The stock remains within its 52‑week range of $2.91 to $17.55.
Transaction History
| MGRX | ▲ Buy | Grant | 100,000 | $0 | 7/28/2026 | View on chart |
| MGRX | ▼ Sell | Open Market | 125,000 | $153K | 11/19/2025 | View on chart |
| MGRX | ▲ Buy | Grant | 100,000 | $0 | 9/9/2025 | View on chart |
| ATXG | ▼ Sell | Open Market | 23,095 | $12K | 9/8/2025 | View on chart |
| ATXG | ▲ Buy | Grant | 23,095 | $0 | 8/11/2025 | View on chart |
| MGRX | ▲ Buy | Grant | 25,000 | $0 | 4/10/2025 | View on chart |
| MGRX | ▼ Sell | Open Market | 108,426 | $35K | 6/26/2024 | View on chart |
| MGRX | ▼ Sell | Open Market | 16,574 | $5K | 6/25/2024 | View on chart |
| MGRX | ▲ Buy | Grant | 100,000 | $0 | 6/3/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
MGRX Shares Drop 12% After Hours Amid $2.5M Investment Announcement
Mangoceuticals shares fell 12% in after‑hours trading after the company announced a $2.5 million investment in its MangoRx IP. The deal provides an initial $1.75 million tranche and additional funding from strategic investors. Despite the funding, the market reacted negatively, pulling the stock lower. The move highlights the volatility around the company’s valuation.
MGRX Shares Drop 12% After Hours Amid $2.5M Investment Announcement. Mangoceuticals shares fell 12% in after‑hours trading after the company announced a $2.5 million investment in its MangoRx IP. The deal provides an initial $1.75 million tranche and additional funding from strategic investors. Despite the funding, the market reacted negatively, pulling the stock lower. The move highlights the volatility around the company’s valuation.